Skip to main content
NASDAQ:INZY

Inozyme Pharma Competitors

$15.49
+0.30 (+1.97 %)
(As of 05/14/2021 12:49 PM ET)
Add
Compare
Today's Range
$15.43
$15.97
50-Day Range
$15.85
$21.20
52-Week Range
$14.51
$31.65
Volume1,468 shs
Average Volume57,213 shs
Market Capitalization$363.61 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Inozyme Pharma (NASDAQ:INZY) Vs. KRON, AUPH, PRLD, CMPS, PMVP, and INVA

Should you be buying INZY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Inozyme Pharma, including Kronos Bio (KRON), Aurinia Pharmaceuticals (AUPH), Prelude Therapeutics (PRLD), COMPASS Pathways (CMPS), PMV Pharmaceuticals (PMVP), and Innoviva (INVA).

Kronos Bio (NASDAQ:KRON) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares Kronos Bio and Inozyme Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kronos BioN/AN/AN/A
Inozyme PharmaN/AN/AN/A

Institutional and Insider Ownership

69.8% of Inozyme Pharma shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Kronos Bio and Inozyme Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kronos BioN/AN/AN/AN/AN/A
Inozyme PharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Kronos Bio and Inozyme Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kronos Bio00403.00
Inozyme Pharma00403.00

Kronos Bio presently has a consensus price target of $43.6667, indicating a potential upside of 66.86%. Inozyme Pharma has a consensus price target of $36.00, indicating a potential upside of 132.26%. Given Inozyme Pharma's higher possible upside, analysts clearly believe Inozyme Pharma is more favorable than Kronos Bio.

Summary

Inozyme Pharma beats Kronos Bio on 2 of the 2 factors compared between the two stocks.

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Aurinia Pharmaceuticals and Inozyme Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%
Inozyme PharmaN/AN/AN/A

Institutional & Insider Ownership

51.2% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Inozyme Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and Inozyme Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurinia Pharmaceuticals$320,000.004,768.50$-123,850,000.00($0.89)-13.38
Inozyme PharmaN/AN/AN/AN/AN/A

Inozyme Pharma has lower revenue, but higher earnings than Aurinia Pharmaceuticals.

Analyst Recommendations

This is a summary of recent recommendations for Aurinia Pharmaceuticals and Inozyme Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurinia Pharmaceuticals00703.00
Inozyme Pharma00403.00

Aurinia Pharmaceuticals presently has a consensus target price of $28.00, indicating a potential upside of 135.10%. Inozyme Pharma has a consensus target price of $36.00, indicating a potential upside of 132.26%. Given Aurinia Pharmaceuticals' higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Inozyme Pharma.

Summary

Inozyme Pharma beats Aurinia Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Prelude Therapeutics (NASDAQ:PRLD) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Prelude Therapeutics and Inozyme Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prelude TherapeuticsN/AN/AN/A
Inozyme PharmaN/AN/AN/A

Institutional & Insider Ownership

76.2% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Inozyme Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Prelude Therapeutics and Inozyme Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/AN/AN/AN/A
Inozyme PharmaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Prelude Therapeutics and Inozyme Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prelude Therapeutics03202.40
Inozyme Pharma00403.00

Prelude Therapeutics presently has a consensus target price of $55.80, indicating a potential upside of 33.52%. Inozyme Pharma has a consensus target price of $36.00, indicating a potential upside of 132.26%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than Prelude Therapeutics.

Summary

Inozyme Pharma beats Prelude Therapeutics on 3 of the 4 factors compared between the two stocks.

COMPASS Pathways (NASDAQ:CMPS) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Earnings & Valuation

This table compares COMPASS Pathways and Inozyme Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A
Inozyme PharmaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for COMPASS Pathways and Inozyme Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
COMPASS Pathways00703.00
Inozyme Pharma00403.00

COMPASS Pathways presently has a consensus target price of $70.80, indicating a potential upside of 108.54%. Inozyme Pharma has a consensus target price of $36.00, indicating a potential upside of 132.26%. Given Inozyme Pharma's higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than COMPASS Pathways.

Profitability

This table compares COMPASS Pathways and Inozyme Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
COMPASS PathwaysN/AN/AN/A
Inozyme PharmaN/AN/AN/A

Institutional & Insider Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 69.8% of Inozyme Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Inozyme Pharma beats COMPASS Pathways on 2 of the 3 factors compared between the two stocks.

Inozyme Pharma (NASDAQ:INZY) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Inozyme Pharma and PMV Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inozyme PharmaN/AN/AN/AN/AN/A
PMV PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Inozyme Pharma and PMV Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inozyme Pharma00403.00
PMV Pharmaceuticals01302.75

Inozyme Pharma currently has a consensus target price of $36.00, indicating a potential upside of 132.26%. PMV Pharmaceuticals has a consensus target price of $38.00, indicating a potential upside of 19.05%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Inozyme Pharma is more favorable than PMV Pharmaceuticals.

Profitability

This table compares Inozyme Pharma and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inozyme PharmaN/AN/AN/A
PMV PharmaceuticalsN/AN/AN/A

Institutional and Insider Ownership

69.8% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Inozyme Pharma beats PMV Pharmaceuticals on 4 of the 4 factors compared between the two stocks.

Inozyme Pharma (NASDAQ:INZY) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Inozyme Pharma and Innoviva's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inozyme PharmaN/AN/AN/AN/AN/A
Innoviva$261.02 million4.96$157.29 million$1.438.94

Innoviva has higher revenue and earnings than Inozyme Pharma.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Inozyme Pharma and Innoviva, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inozyme Pharma00403.00
Innoviva10001.00

Inozyme Pharma currently has a consensus target price of $36.00, indicating a potential upside of 132.26%. Innoviva has a consensus target price of $10.00, indicating a potential downside of 21.88%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Inozyme Pharma is more favorable than Innoviva.

Profitability

This table compares Inozyme Pharma and Innoviva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inozyme PharmaN/AN/AN/A
Innoviva67.16%53.99%28.92%

Institutional and Insider Ownership

69.8% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 71.5% of Innoviva shares are owned by institutional investors. 0.3% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Innoviva beats Inozyme Pharma on 6 of the 9 factors compared between the two stocks.


Inozyme Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kronos Bio logo
KRON
Kronos Bio
1.7$25.48+0.4%$1.42 billionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$11.91+8.0%$1.40 billion$320,000.00-8.10
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$42.57+8.0%$1.39 billionN/A0.00Earnings Announcement
Insider Selling
Gap Up
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$33.97+3.5%$1.31 billionN/A0.00Earnings Announcement
Analyst Report
Gap Up
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$31.99+9.3%$1.30 billionN/A0.00Gap Up
Innoviva logo
INVA
Innoviva
1.1$12.78+0.2%$1.29 billion$261.02 million6.52
Endo International logo
ENDP
Endo International
1.5$5.54+0.2%$1.29 billion$2.91 billion-8.15Analyst Revision
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$25.40+0.6%$1.28 billionN/A-2.75
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.69+4.3%$1.28 billion$82.27 million-16.32Earnings Announcement
Analyst Revision
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$30.45+4.8%$1.27 billion$230,000.00-14.16Gap Up
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$29.24+0.3%$1.27 billion$6.20 million-12.82Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.6$28.53+6.7%$1.23 billion$29.54 million-7.57Analyst Report
Gap Up
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.5$35.88+7.0%$1.23 billionN/A-19.93Earnings Announcement
Analyst Revision
Gap Up
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$18.95+1.2%$1.22 billion$73.41 million-4.01Analyst Report
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.81+2.7%$1.17 billion$59.70 million-198.10
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$32.16+3.0%$1.15 billionN/A0.00Earnings Announcement
News Coverage
Gap Down
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$17.92+5.5%$1.14 billion$175.34 million-10.54Gap Down
Omeros logo
OMER
Omeros
1.4$18.55+1.2%$1.14 billion$111.81 million-7.79Earnings Announcement
Analyst Downgrade
Analyst Revision
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.16+1.3%$1.14 billion$4.23 million-8.47
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$21.01+1.1%$1.11 billion$4.23 million-15.56
Shattuck Labs logo
STTK
Shattuck Labs
1.5$25.59+2.2%$1.10 billionN/A0.00Earnings Announcement
Insider Selling
Gap Up
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.6$27.31+1.1%$1.09 billion$800.40 million25.76Analyst Report
News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.5$48.34+4.2%$1.08 billionN/A0.00Analyst Downgrade
Analyst Revision
Gap Down
Zogenix logo
ZGNX
Zogenix
2.0$19.15+0.5%$1.07 billion$3.65 million-2.01Insider Buying
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$33.87+0.4%$1.06 billionN/A-2.42Analyst Upgrade
Insider Selling
Analyst Revision
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$22.69+6.7%$1.06 billionN/A-7.46
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$28.58+2.3%$1.05 billion$57.05 million0.00Earnings Announcement
Analyst Revision
News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.54+0.7%$1.02 billion$227.19 million51.50Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$51.72+2.7%$1.02 billion$122.47 million-28.42
MannKind logo
MNKD
MannKind
1.4$4.31+6.5%$1.00 billion$63.04 million-20.52Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$14.84+3.3%$990.88 million$42.12 million-10.99Earnings Announcement
Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$17.66+5.3%$981.33 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
OLMA
Olema Pharmaceuticals
1.6$24.62+2.2%$966.89 millionN/A0.00Earnings Announcement
Lockup Expiration
Analyst Revision
News Coverage
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$28.32+2.1%$965.56 millionN/A-13.05Earnings Announcement
News Coverage
Radius Health logo
RDUS
Radius Health
1.1$20.58+2.1%$951.95 million$173.32 million-8.43Earnings Announcement
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$14.04+1.5%$943.65 millionN/A-5.92
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$19.87+1.6%$931.74 million$322.36 million141.93Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$20.34+5.6%$919.97 millionN/A-7.51Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.60+5.1%$917.13 millionN/A-26.48Analyst Revision
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$25.14+3.6%$889.51 millionN/A0.00News Coverage
Gap Up
Epizyme logo
EPZM
Epizyme
1.9$9.12+4.9%$884.13 million$23.80 million-4.09Analyst Report
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.8$18.56+2.4%$873.55 million$1.52 million-9.87Earnings Announcement
Analyst Upgrade
Analyst Revision
Affimed logo
AFMD
Affimed
1.6$9.11+2.7%$870.82 million$23.96 million-15.44News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$8.57+1.4%$870.63 million$120,000.00-3.17Earnings Announcement
Unusual Options Activity
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$21.67+4.5%$870.51 millionN/A-7.47Insider Selling
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.4$17.69+4.0%$869.48 millionN/A0.00News Coverage
Gap Up
Prothena logo
PRTA
Prothena
2.1$23.08+6.3%$865.33 million$810,000.00-9.02Earnings Announcement
Analyst Report
Analyst Revision
Merus logo
MRUS
Merus
1.8$22.07+0.3%$843.70 million$31.13 million-7.19Analyst Revision
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.69+4.7%$839.93 million$35.22 million-5.61Analyst Downgrade
Nkarta logo
NKTX
Nkarta
1.8$27.89+14.2%$786.93 millionN/A0.00Earnings Announcement
News Coverage
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.